title: CD200 expression in patients with Multiple Myeloma: another piece of the puzzle.
abstract: CD200 is a relatively ubiquitously expressed molecule that plays a role in cancer immune evasion through interaction with its receptors. High expression levels of CD200 have been described in different human malignancies. For example, CD200 has been shown to be targeted after RAS/RAF/MEK/ERK activation in melanoma. Here we present the analysis of CD200 expression in human Multiple Myeloma (MM) samples. We found that CD200-positive cells express ERK and p-ERK. Moreover, UO126, a MEK inhibitor, reduces CD200 expression. Furthermore, we observe that CD200-positive cells show reduced immunogenicity compared to normal lymphocytes and that such immunogenicity increases when UO126 is used. We therefore hypothesize that CD200 expression in MM could suppress antitumor response and that anti-CD200 treatment might be therapeutically beneficial in CD200-expressing tumors.
authors.affiliation: Department of Experimental Oncology, Mediterranean Institute of Oncology (IOM), Viagrande, Catania, Italy.
authors.forename: Concetta
authors.initials: C
authors.lastname: Conticello
authors.forename: Raffaella
authors.initials: R
authors.lastname: Giuffrida
authors.forename: Nunziatina
authors.initials: N
authors.lastname: Parrinello
authors.forename: Simona
authors.initials: S
authors.lastname: Buccheri
authors.forename: Luana
authors.initials: L
authors.lastname: Adamo
authors.forename: Maria Rita
authors.initials: MR
authors.lastname: Sciuto
authors.forename: Cristina
authors.initials: C
authors.lastname: Colarossi
authors.forename: Eleonora
authors.initials: E
authors.lastname: Aiello
authors.forename: Annalisa
authors.initials: A
authors.lastname: Chiarenza
authors.forename: Alessandra
authors.initials: A
authors.lastname: Romano
authors.forename: Edvige
authors.initials: E
authors.lastname: Salomone
authors.forename: Massimo
authors.initials: M
authors.lastname: Gulisano
authors.forename: Rosario
authors.initials: R
authors.lastname: Giustolisi
authors.forename: Francesco
authors.initials: F
authors.lastname: Di Raimondo
mesh_terms: D015703:Antigens, CD / Q000378:metabolism*; D000954:Antigens, Surface / Q000378:metabolism; D014408:Biomarkers, Tumor / Q000378:metabolism; D002070:Butadienes / Q000494:pharmacology; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology / Q000378:metabolism; D002478:Cells, Cultured; D004791:Enzyme Inhibitors / Q000494:pharmacology; D006801:Humans; D008213:Lymphocyte Activation / Q000187:drug effects; D007959:Lymphocyte Culture Test, Mixed; D020935:MAP Kinase Signaling System / Q000187:drug effects / Q000502:physiology; D009101:Multiple Myeloma / Q000276:immunology / Q000378:metabolism* / Q000473:pathology; D009570:Nitriles / Q000494:pharmacology; D064446:Orexin Receptors; D011956:Receptors, Cell Surface / Q000378:metabolism; D019139:Tumor Escape / Q000502:physiology
chemical_list: D015703:Antigens, CD; D000954:Antigens, Surface; D014408:Biomarkers, Tumor; D002070:Butadienes; C477337:CD200R1 protein, human; D004791:Enzyme Inhibitors; D009570:Nitriles; D064446:Orexin Receptors; D011956:Receptors, Cell Surface; C113580:U 0126; C042739:antigens, CD200
keywords: BM; CD200; ERK pathway; ISS; Immunoregulation; International Staging System; MEK inhibitor; MLR; MM; Mixed Lymphocyte Reaction; Multiple Myeloma; PC; T cells; bone marrow; plasma cell